Galera announces presentation of supplemental analysis of phase 3 roman trial at european congress on head and neck oncology

Malvern, pa., march 10, 2023 (globe newswire) -- galera therapeutics, inc. (nasdaq: grtx), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the presentation of a net treatment benefit analysis of phase 3 roman results at the 10th european congress on head and neck oncology (echno), taking place march 8-11, 2023, in lisbon, portugal. the analysis further demonstrates the overall impact of avasopasem manganese (avasopasem) in reducing the burden of severe oral mucositis (som). galera's new drug application (nda) in the u.s. for avasopasem is currently under u.s. food and drug administration (fda) priority review for radiotherapy (rt)-induced som in patients with head and neck cancer undergoing standard-of-care treatment.
GRTX Ratings Summary
GRTX Quant Ranking